New tech aims to prevent low blood sugar in seniors with diabetes

NCT ID NCT03078491

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an enhanced continuous glucose monitor (eCGM) linked to a decision-support system can help older adults (65+) with type 1 diabetes manage their blood sugar. The system automatically uploads glucose, insulin, and activity data to give personalized insulin dose recommendations. The goal was to reduce time spent in dangerously low blood sugar (hypoglycemia). 168 participants were enrolled, and the study compared those using the eCGM system to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

enhanced continuous glucose monitor (eCGM) with clinical decision support

What this could lead to

If successful, this could provide a practical way for older adults with type 1 diabetes to better control their blood sugar and reduce dangerous low blood sugar episodes.

What could go wrong

This is a completed study, so results are available, but the approach relies on technology that may not work for everyone, and the benefits may not apply to those with very poor glucose control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLDER ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoglycemia type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Joslin Diabetes Center

    Boston, Massachusetts, 02215, United States